Back to News
Market Impact: 0.35
What Moderna (MRNA) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & Biotech
Moderna raised its 2026 revenue-growth outlook after reporting higher third-quarter sales and returning to quarterly profitability. COVID-19 vaccine demand and international partnerships supported results; the article provides no specific revenue, profit, or growth figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
MRNA0.70
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Stocks making the biggest moves midday: Nvidia, Moderna, IonQ, Airbnb, Firefly Aerospace & more
- While biotech bets swing on trial data, this dividend payer gained 72% since 2024
- 5 Things Investors Need to Know About Friday's Markets
- Our top 10 things to watch in the stock market Friday
- Stocks making the biggest moves premarket: Moderna, Airbnb, Cloudflare, Affirm & more